FORMULATION AND IN-VITRO EVALUATION OF EXTENDED RELEASE MATRIX TABLETS OF ANTI-PSYCHOTIC AGENT: A SEROTONIN ANTAGONIST-QUETIAPINE FUMERATE

MS SANIYA KHAN; Dr M SUNITHA; Dr P SHASHIDHAR

Volume : VII, Issue : II, February - 2018

FORMULATION AND IN-VITRO EVALUATION OF EXTENDED RELEASE MATRIX TABLETS OF ANTI-PSYCHOTIC AGENT: A SEROTONIN ANTAGONIST-QUETIAPINE FUMERATE

Ms Saniya Khan, Dr M Sunitha, Dr P Shashidhar

Abstract :

The objective of present work is to prepare and optimize extended release tablets of Quetiapine Fumarate which is an atypical antipsychotic agent used in the treatment of schizophrenia, bipolar disorder and major depressive disorder. The peaks of FTIR spectrum of API Quetiapine Fumarate was found to be compatible and no interference with the excipients used in present study. An attempt was made to prepare extended release tablets using Methocel E 50, Sodium Alginate and combination of both as release retarding agents of total 10 trials. Based on the blend characterization and in vitro evaluation parameters trials T-03 of Methocel E 50, T-07 of Methocel E-50 and Sodium alginate T-10 of Sodium Alginate were taken for optimizing and reproducible trials and based on comparative in-vitro drug release of these three trials, trial T-7 was taken for one month stability studies and determination of order of release rate kinetics. After one month accelerated stability studies, the drug release was found to be 96.33 % in 8 hrs. The order of release was found to be as 0.9954 for Koresmeyer Peppas release rate kinetics>0.9831 for Higuchi�s model release rate kinetics>0.9823 for Zero order kinetics>0.8409 for First order kinetics. Based on the results obtained it was confirmed that release of drug from prepared in-house Quetiapine Fumarate extended release tablets fallows Koresmeyer Peppas with regression coefficient value 0.9954.